While the current influx of biotech IPOs is a positive sign for the industry, historical data shows that excessive IPO activity often coincides with tops in major biotech indices like the XBI. This is a counterintuitive risk for investors to monitor.

Unlike the speculative bubbles of 1999 and 2021, the current IPO market lacks the massive first-day price surges characteristic of euphoria. According to economist Owen Lamont, these more restrained initial returns suggest that investor demand is rational rather than frenzied, serving as a real-time sentiment gauge.

Despite high market valuations, the current environment is a massive IPO drought, comparable to the 1930s or 1970s. Historically, equity market bubbles are defined by a huge wave of IPOs and secondary offerings. The absence of this issuance is a strong counterargument to bubble claims.

The current market exhibits several classic signs of a major peak: rampant public speculation, a massive increase in equity supply from IPOs and secondary offerings, and a central bank that is beginning a tightening cycle. This powerful combination of factors points towards a high probability of a sustained decline in risk assets.

A key indicator of a bubble's final stage, observed only four times in U.S. history (1929, 1972, 2000, 2021), is when speculative, high-beta stocks that led the rally start to fall sharply while blue-chip indices continue to grind higher. This market divergence is a 'primal scream' that a crash is imminent.

A market enters a bubble when its price, in real terms, exceeds its long-term trend by two standard deviations. Historically, this signals a period of further gains, but these "in-bubble" profits are almost always given back in the subsequent crash, making it a predictable trap.

Analyst Ross Gerber compares the euphoria around the SpaceX IPO to the AOL Time Warner merger of the late 90s. He warns that a wave of mega-IPOs (SpaceX, Anthropic, OpenAI) could put excessive pressure on markets to absorb the new stock, potentially marking the beginning of a bubble.

For the past decade, the market benefited from shrinking equity supply via buybacks. Jones warns this trend is about to reverse. A wave of large IPOs will flood the market with new stock, creating a significant headwind as supply outstrips demand, especially for the tech sector.

Academic research covering decades of data reveals a clear trend: newly public companies tend to underperform the broader market by an average of 20 percentage points in the three years following their IPO. This underperformance is even more pronounced for high-valuation firms, serving as a cautionary tale for investors chasing IPO hype.